Mangoceuticals (MGRX) Cash from Financing Activities (2023 - 2025)

Mangoceuticals (MGRX) has 3 years of Cash from Financing Activities data on file, last reported at $2.1 million in Q4 2025.

• For the quarter ending Q4 2025, Cash from Financing Activities rose 85.61% year-over-year to $2.1 million; the trailing twelve-month figure through Dec 2025 stood at $7.3 million (up 76.12% YoY), and the FY2025 full-year result was $7.3 million, up 76.12% from the prior year.
• Cash from Financing Activities climbed to $2.1 million in Q4 2025, from $1.6 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $5.0 million in Q1 2023 to a low of $267500.0 in Q1 2024.
• A 3-year average of $1.7 million and a median of $1.3 million in 2025 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities tumbled 94.65% in 2024 and surged 754.21% in 2025, its largest moves.
• Tracing MGRX's Cash from Financing Activities over 3 years: stood at $1.2 million in 2023, then declined by 6.46% to $1.1 million in 2024, then jumped by 85.61% to $2.1 million in 2025.
• Business Quant data shows MGRX's Cash from Financing Activities at $2.1 million in Q4 2025, $1.6 million in Q3 2025, and $1.3 million in Q2 2025.